Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancer that causes death and has poor prognosis, resulting in patient survival rates in the range of 3%-5%. 1 However, between 20% and 35% of patients are eligible for this invasive procedure due to the delayed diagnosis of HCC in patients with advanced cancer.
2 Current treatment modalities for HCC include surgical tumor removal or transcatheter arterial embolization, chemotherapy, and external radiotherapy.
The chemotherapeutic drug doxorubicin (Dox) is commonly used to treat HCC. However, clinical studies have shown its serious side effects, such as dose-dependent cardiotoxicity and hepatotoxicity. 3 Previous researches recently have revealed that nano-sized carrier enhance the accumulation of Dox in the tumor site and decrease the side effect. 4, 5 Intra-arterial administration of therapeutic radiopharmaceuticals and chemotherapeutic agents can deliver a tumoricidal dose with less non-tumorous hepatic tissue damage. 6, 7 However, transcatheter arterial embolization of yttrium-90 ( 90 Y)-micospheres requires accurate skill and the use of specialized equipment, and the skeletal accumulation of 90 Y could result in bone marrow depression. 188 Re) is now considered as a better isotope for in vivo studies and clinical applications in both the imaging and therapeutic treatment of HCC. 9, 10 Since 188 Re (t 1/2 =16.9 hours) decays by 15% gamma emission (E γ =155 keV) and by 85% beta emission (E β−max =2.12 meV), its incorporation into polymeric micelles, which composed of amphiphilic block copolymers for drug delivery, [11] [12] [13] could have both diagnostic and therapeutic applications. [14] [15] [16] [17] [18] [19] The high β-energy emission (2.1 meV) of 188 Re provides the optimal therapeutic dose and deep tissue penetration for cancer therapy as previously studies described. 17, [20] [21] [22] By the enhanced permeability and retention (EPR) effect, nano-sized carrier could passive targeting 23 and efficiently accumulate in tumors. [24] [25] [26] [27] In this study, we evaluated a nano-sized drug delivery system based on methoxy-poly (ethylene glycol)-blockpoly(ε-caprolactone) (mPEG-b-PCL) micelles 28 containing radiopharmaceuticals -
188
Re and chemotherapeutic agentsDox for combined radio/chemotherapy. The multifunctional micelles loaded with Dox and labeled with 188 Re were developed to synergistically enhance cancer therapy. By using a murine model with luciferase-transfected BNL tumor cells (BNL/Luc) HCC, both the therapeutic efficacy and mechanism of this delivery system were evaluated.
Materials and methods

Preparation of 188 re-Dox micelles
The amphiphilic block copolymers, including mPEG-b-PCL and Fmoc-NH-PEG-b-PCL, were synthesized by the ringopening polymerization of ε-caprolactone, and deprotected by 20% piperidine in dimethylformamide. 15, 29 Conjugation of diethylene triamine pentaacetic acid (DTPA) dianhydride with the amino group of N 2 H-PEG-b-PCL to synthesis the DTPA-PEG-b-PCL as described previously. 17, 30 The molecular weights of copolymers were characterized by 1 H nuclear magnetic resonance (NMR, Bruker Avance-500 MHz FT-NMR; Bruker Corporation, Billerica, MA, USA) and gel permeation chromatography (Waters 510 pump/410 differential refractometer).
The doxorubicin-loaded DTPA micelles (Dox micelles) were prepared by the solvent evaporation method. 29, 31, 32 The concentration of Dox was quantified by determining the absorbance at 480 nm with a UV-visible spectrophotometer (BioMate 3S, Thermo Electron Corporation, Hudson, NH, USA). The drug encapsulation efficiency is the amount of drug encapsulated divided by the amount of drug added multiplied by 100%. The mean diameters of the micelles were characterized with a Delsa™ Nano Particle Analyzer (Beckman Coulter, Fullerton, CA, USA). The morphology of the micelles was observed by H-7650 transmission electron microscopy (TEM, Hitachi Ltd., Tokyo, Japan).
The morphology of the micelles was observed by H-7650 TEM (Hitachi Ltd). The radiolabeling yields of the 188 Re-DTPA-micelles were determined by a radio-thin layer chromatography imaging scanner (AR2000, Bioscan, Washington, DC, USA Re-Dox micelles were placed in a dialysis bag (molecular weight cutoff 3.5 kDa), and the dialysis bag was incubated in 50 mL of phosphate-buffered saline (PBS) (pH ∼7.4) with gently stirring at 37°C, and the release medium was collected at predetermined time intervals. The release of Dox was quantified using high-performance liquid chromatography (HPLC), using a Waters Symmetry C18 reversed-phase column (150 mm ×3.9 mm, 5 mm) and a Waters HPLC instrument (Waters HPLC Alliance 2695 with a Waters 2487 dual λ absorbance detector; Waters, Milford, MA, USA). The mobile phase consisted of a 0.1% trifluoroacetic acid solution (pH=3.0) and acetonitrile at a flow rate of 1 mL/min. Dox was detected using a λ absorbance detector with a wavelength of 480 nm. The released 188 Re from the 188 Re-Dox micelles was quantified using a gamma-counter (Cobra series Model 5003, Packard Instrument Company, Inc., Meriden, CT, USA). All results are the mean ± standard deviation.
establishment of the murine hepatocellular carcinoma model
Orthotopic murine liver tumor was generated in Balb/c mice using the BNL/Luc cell line. Female Balb/c athymic (nut/ nut) nude mice 5-6 weeks of age were purchased from the National Laboratory Animal Center (Taipei, Taiwan . After intravenous injection 1, 4, 24, and 48 hours, the SPECT images merged with CT images were obtained from the animal in exactly the same position as described previously. 17 The tumor-bearing mice (n=3 per time point) were sacrificed 1, 4, 8, 24, and 48 hours after injection of 188 Re-Dox micelles, and then the blood, heart, liver, spleen, lung, kidney, smooth muscle, small intestine, urinary bladder, bone, brain, and tumors were collected, and the radioactivity of those organs was measured by a gamma counter. Distribution data were shown as the percentage of injected dose per gram of organs (ID%/g). Each column represents the mean ± standard deviation.
The biodistribution of doxorubicin was studied by ex vivo fluorescence images using an IVIS imaging system. After 188 Re-Dox micelles injected 48 hours, the mice were sacrificed and obtained the heart, liver, spleen, lung, kidney, intestine, and tumors. Aforementioned organs were isolated to estimate the organs distribution of doxorubicin.
After the biodistribution studies, tumors and livers of mice were frozen, and embedded in optimal cutting temperature compound (Tissue Tek, Sakura, Torrance, CA, USA) for the frozen sections. The frozen sections were placed in contact with a BASMS 2040 imaging plate (Fujifilm, Tokyo, Japan) for the autoradiography, and the images were analyzed by an FLA-5100 reader (Fujifilm) and Multi Gauge V3.0 software (Fujifilm).
To identify the cluster of differentiation 31 (CD-31) expression and the distribution of doxorubicin in the tumor tissues (n=3) by immunofluorescence staining, the BNL/Luc tumor-bearing mice were intravenously administered with 188 Re-Dox micelles at 10 mg/kg of doxorubicin. The tumor tissues were collected at 24 and 48 hours after injection, frozen, optimal cutting temperature embedded, and sectioned. The sections were washed continuous three times with PBS, then fixed in acetone for 15 minutes. The sections slide was farther blocked with 5% normal goat serum for 10 minutes at room temperature. The rat-anti-mouse CD-31 monoclonal antibody (rat anti-mouse, diluted 1:100, BioLegend, San Diego, CA, USA) were overlaid all sections with at 4°C overnight. The fluorescein isothiocyanate-labeled goat-anti-rat IgG (diluted 1:400, Sigma, St Louis, MO, USA) was added on slide and incubated at room temperature for 1 hour. The CD-31 staining slides were observed under a fluorescence microscope (Olympus Corporation, Tokyo, Japan).
Anti-tumor efficacy of Re on days 0, 6, and 12. Body weight changes were measured during observation days. The mice death dates were recorded for the survival curve by the Kaplan-Meier method. Survival evaluate of all groups was analyzed by log-rank test, and when ,0.05, P-value was considered significant difference. The tumor growth inhibition (TGI) percentage of mice was calculated by the relative tumors volume at the mice sacrificed time points.
The therapeutic responses were monitored by bioluminescence imaging during observation days. The BNL/Luc tumor of mice was imaged and measured by IVIS system by Living Imaging software (Xenogen) on days 0, 6, 13, 19, and 26.
The 188 Re-Dox micelles were administered via the tail vein with 10 mg/kg of doxorubicin and 22.2 MBq of 188 Re. The tumor tissues (n=3) were collected at 24, 36, 48 hours after injection. For the hematoxylin and eosin (H&E) staining and immunohistochemical studies, all of the tumor tissues were formalin-fixed and paraffin-embedded. The necrosis in tumor tissue was detected by nicotinamide adenine dinucleotide phosphate (NADPH)-diaphorase staining. 35 The section slides were reacted with NADPH-diaphorase reaction solution (10 mL of 1 M Trizma solution) containing 80 mg NADPH and 5 mg nitroblue tetrazolium for 30 minutes at 37°C. The section slides were also analyzed by proliferating cell nuclear antigen (PCNA) immunohistochemical staining for the proliferation study as described previously. 18 The liver and spleen tissues (n=3) were collected at 24, 48 hours, and 7 days after the injection of the All results are the mean ± standard deviation from ten distinct regions of each of the three tumors per experimental group.
Results
characterization of the 188 re-Dox micelles
We synthesized mPEG-b-PCL and DTPA-PEG-b-PCL as described previously ( Figure 1A) . 17 The molecular weights (M n,NMR ) and degree of polymerization (DP PCL ) of mPEG-b-PCL and DTPA-PEG-b-PCL copolymers were 15,400 Da (DP PCL : 91.1) and 14,000 Da (DP PCL : 78.9), respectively, as determined by 1 H NMR spectroscopy. The conjugation efficiency of DTPA dianhydride to NH 2 -PEG-PCL was 76.8% as described previously. 17 The Dox micelles were observed by TEM ( Figure 1B ), exhibited spherical shape with sizes consistent with those observed by DLS ( Figure 1C ). The size of Dox micelles using various D/P ratios for Dox loading ranged from 107.5 to 194.0 nm (Table 1 and Figure 1C ). The radiochemical purities of the 188 Re-Dox micelles with D/P ratios of 1:5, 1:10, and 1:20 were 89.4%, 94.1%, and 90.1%, respectively ( Figure 1D ). The Dox micelles with a D/P ratio of 1:5 or 1:20 were larger in particle sizes with lower encapsulation efficiencies and radiochemical purities than those with a D/P ratio of 1:10 ( Table 1) .
The in vitro release profiles of 188 Re ( Figure 2A ) and Dox ( Figure 2B ) from the 188 Re-Dox micelles in PBS solution at pH 5.0 and 7.4 were assessed. A two-phase release profile was detected with a relatively fast release in the first phase after 8 hours, followed by a sustained and slower release over a prolonged period of time.
Micro-sPecT/cT imaging and biodistribution of the 188 re-Dox micelles in mice bearing BNl/luc tumors The biodistributions of the 188 Re-Dox micelles were evaluated in mice bearing BNL/Luc tumors. The micro-SPECT/ CT imaging discovered that the radioactivity accumulated in both the liver and tumor at 1, 4, 24, and 48 hours after the injection of the 188 Re-Dox micelles ( Figure 3A) . To confirm the biodistributions of the 188 Re-Dox micelles from the micro-SPECT/CT images, autoradiography was performed. The autoradiography studies clearly showed significant accumulation of radioactivity from the 188 Re-Dox micelles in the liver beginning 4 hours after injection ( Figure 3B ). However, the tumor accumulation of radioactivity also increased with time after the injection.
The highest accumulation had occurred in the liver, followed by in the tumor, spleen, lung, and kidney at 1 hour after the injection of the 188 Re-Dox micelles ( Figure 3C ). The radioactivity in the blood and kidney decreased quickly over the time course, with the urinary bladder displaying increased radioactivity.
The ex vivo biodistribution of Dox was evaluated in mice bearing BNL/Luc tumors. Images obtained by the IVIS imaging system revealed the accumulation of Dox in the heart, liver, tumor, spleen, lung, and kidney at 48 hours after the injection of the 188 Re-Dox micelles. As shown in Figure 4A -C, higher bioluminescence and fluorescence from Dox occurred in the tumor compared with other major organs.
The distribution of Dox correlation with the blood vessels between liver and tumor was evaluated; tissue sections were stained with a CD-31 immunostaining ( Figure 4D ). This analysis shown that the 188 Re-Dox micelles extravagated from the blood vessels and that doxorubicin delivery was more accumulation in tumors compared with in normal liver.
anti-tumor effect of the The antitumor efficacy of the 188 Re-Dox micelles was compared with that of the 188 ReO 4 and the Dox-micelles. As shown in Figure 5B , the tumor burden was measured and quantified based on the luminescence intensity, as performed in Figure 5A . The average photon flux was measured as a function of time after the treatments. The ReO 4 alone, and Dox micelle alone groups, respectively. There was no significant difference among the average survival times of these three groups (P.0.05). On the contrary, the survival rates of the hepatoma mice treated with the 188 Re-Dox micelles were 80% on day 31. To further examine the therapy effect of the or control. The PCNA immunostaining revealed that the cell proliferation was significantly decreased in the tumors treated with the 188 Re-Dox micelles (∼19.6%±6.8%) compared with the tumors treated with 188 ReO 4 alone (∼50.7%±8.7%; P,0.05), with Dox micelles alone (∼50.7%±8.7%; P,0.05), or with PBS alone (control mice) (∼68.0%±9.6%; P,0.05) ( Figure 6B ). The histological analysis demonstrated that 188 Re-Dox micelles could not cause significant toxicity in normal liver and spleen as shown in Figure 6C .
Discussion
The Dox micelles with a D/P ratio of 1:10 had the highest encapsulation efficiency of 98.2% and a radiochemical purity of 94.1% ( Figure 1 and Table 1 ). It had reported that nanoparticles with a size arranging from 10 to 100 nm are more efficient as drug delivery systems and exhibit high cellular uptake and tumor accumulation, [25] [26] [27] whereas the reticuloendothelial system filters away nanoparticles with sizes larger than 200 nm. 36, 37 The Dox micelle with a D/P ratio of 1/10 was employed as the drug carrier for this study.
Results of in vitro release profiles of 188 Re and Dox indicate that the drug release from the 188 Re-Dox micelles would occur under acidic or neutral conditions, which is under physiological conditions (Figure 2) . Re-Dox micelles delayed the appearance and decreased the intensity of luminescence by up to days 26; however, the expression of luminescence did not decrease in the other groups. This suggests that the 188 Re-Dox micelles were the inhibitoriest toward tumor growth compared with the other single treatments.
Although we observed body weight loss in mice receiving the 188 Re-Dox micelles, all mice administered with triple doses of the 188 Re-Dox micelles had survived on day 26, indicating that the combination of radiotherapy and chemotherapy mediated by the 188 Re-Dox micelles did not cause obvious toxicity ( Figure 5 ).
In pathology studies ( Figure 6 ), results of H&E staining indicated that more necrosis was seen in tumors treated with the 188 Re-Dox micelles, such as coagulation, vacuolation, and decreased nuclear staining in tumor tissues as described previously. 18 This was in good agreement with the loss of NADPH-diaphorase activity. 35 The tumor tissue sections of all experiment groups were stained with NADPH-diaphorase staining for the assessment of tissue viability. Necrotic tissue in tumor sections showed loss of NADPH-diaphorase activity. 35 As shown in Figure 6A , the tumor treated with 188 Re-Dox micelles had more necrotic features than that treated with 188 ReO 4 alone or Dox micelles alone. PCNA staining shown high expression in tumors treated with 188 ReO 4 , Dox micelles, and PBS alone, but very low in tumors treated with the 188 Re-Dox micelles ( Figure 6B ). According to the results of immunohistochemical staining, the 188 ReDox micelles cause cell death through necrosis. These imply that the treatment with the 188 Re-Dox micelles could greatly increase tumor necrosis and reduce the tumor proliferation but not cause significant toxicity in normal liver and spleen ( Figure 6C ).
Conclusion
In summary, we had prepared and characterized multifunctional 188 Re-Dox micelles simultaneously loaded with doxorubicin and labeled with 188 Re for cancer radiotherapy combined with chemotherapy. The components in the 188 Re-Dox micelles acted synergistically against tumor growth, demonstrating better performance than either component ( 188 ReO 4 or Dox micelles) individually in mice bearing orthotopic liver tumors. Therefore, the 188 Re-Dox micelles would be a synergistic combinatorial treatment modality with both radiotherapy and chemotherapy for orthotopic HCC in mice model.
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